November 20, 2020 -- Immunomic Therapeutics (ITI) and CoImmune Therapeutics have entered into a license agreement for ITI to use CoImmune's proprietary dendritic cell process for certain ITI cell therapy vaccine programs.
ITI will use CoImmune's process for manufacturing and current good manufacturing practice (cGMP) work for the advancement of ITI-1020, ITI's autologous dendritic cell (DC) investigational vaccine loading with messenger RNA encoding pp65-lysosome-associated membrane glycoprotein (LAMP). The vaccine will be used to treat newly diagnosed glioblastoma.
CoImmune is eligible to receive milestone payments from ITI upon the successful achievement of certain agreed-upon goals, such as initiation of clinical studies and regulatory submissions. CoImmune will also be eligible to receive royalty payments based upon net sales of ITI-1020, if the product is approved in the future, the firms said.
Copyright © 2020 scienceboard.net